Jesse Boumelha
@jboumelha
Followers
440
Following
9K
Media
7
Statuses
248
Postdoc in @MiriamMerad lab @SinaiImmunol | Myeloid cells and cancer immunotherapy ✨| Previously @theCrick @JulianDownward
New York, USA
Joined August 2015
RT @MiriamMerad: Few open spots left for our FREE online International 🎓 Immunoschool 🎓! Join leading immunologists Monday, March 10—for an….
0
38
0
RT @MatthewD_Park: I'm excited to share a new review @NatureRevCancer from @MiriamMerad lab @SinaiImmunol led by X-less Chang Moon. We off….
0
25
0
RT @MatthewD_Park: I am thrilled to share a new story, co-led w @MeriemBelabed from @MiriamMerad lab @SinaiImmunol @IcahnMountSinai @TischC….
0
51
0
RT @obenaufa: So excited to share our new paper out in @Nature led by the fabulous @AnaisElewaut and @guillemxtivill providing mechanistic….
0
20
0
RT @cbailey_58: Hot off the press!! 🔥 Check out our work on the origins and impact of ecDNA. This was a team effort involving multiple coll….
0
13
0
RT @JulianDownward: In our new paper just out in Science Advances we investigate mechanisms that may be limiting responses of KRAS mutant l….
science.org
Spatial analysis identified Tregs as a source of local T cell repression, mediating resistance to KRAS-G12C-i and anti–PD-1.
0
43
0
RT @MatthewD_Park: Very grateful to @Cancer_Cell for thoroughly spotlighting our work on hematopoietic aging, IL-1 and DNMT3A, and their vi….
science.org
Age is a major risk factor for cancer, but how aging impacts tumor control remains unclear. In this study, we establish that aging of the immune system, regardless of the age of the stroma and tumor,...
0
13
0
RT @MiriamMerad: I had the most extraordinary celebration of my Lab 20th anniversary this weekend in the Poconos (aka 'Mykonos' to the labb….
0
12
0
RT @JulianDownward: How can we extend responses to KRASG12C drugs? Out now in @NatureComms, combining Revolution Medicines’ RAS(ON) G12C-se….
0
11
0
RT @MatthewD_Park: Thrilled to share our first study on aging from @MiriamMerad lab @IcahnMountSinai @TischCancer @SinaiImmunol in which we….
science.org
Age is a major risk factor for cancer, but how aging impacts tumor control remains unclear. In this study, we establish that aging of the immune system, regardless of the age of the stroma and tumor,...
0
66
0
RT @LeilaAkkari1: Paper 🚨! Ecstatic, proud, grateful …Years of dedication from the whole lab, with the exceptional @djkloosterman and the o….
cell.com
Recycling of cholesterol-rich myelin debris by macrophages leads to the emergence of lipid-laden macrophages (LLMs) in glioblastoma. LLMs support glioblastoma malignancy through transfer of myelin-...
0
91
0
RT @FGinhoux: Just before the summer break! Very proud and excited to share our latest work on tumor macrophage ontogeny ! Spatial temporal….
science.org
Intermediate tumor-associated macrophages (TAMs) emerge first and give rise to two more differentiated TAM populations in pancreatic cancer.
0
40
0
RT @JulianDownward: How does oncogenic KRAS impact anti-tumor immunity in lung cancer? Out now in @CR_AACR, using CRISPR screening we uncov….
aacrjournals.org
COX2 signaling via prostaglandin E2 is a major mediator of immune evasion driven by oncogenic KRAS that promotes immunotherapy and KRAS-targeted therapy resistance, suggesting effective combination...
0
27
0
RT @NUJ_Nature: Great news! @NUJ_Nature and @SpringerNature are pleased to have reached an agreement that ends our pay dispute through a tw….
0
30
0
RT @samhegde2006: Pleased to share our latest work from @MiriamMerad lab @SinaiImmunol, where we try to address the Q: Do tumors alter the….
0
45
0
RT @JulianDownward: We are looking for a post-doc with a background in immunology to work on the impact of RAS oncogenic signaling on the i….
0
62
0
RT @BatlleLab: 🌟Pleased to share our review on Metastatic Colorectal Cancer @NatRevGastroHep . @adriacanyellas .@elenasanchosuil . 👉🏻https:….
0
22
0
RT @giampazolias: Very excited to share our latest work, out today in @ScienceMagazine, on the serendipitous finding that vitamin D ☀️ regu….
0
154
0
RT @F_vanMaldegem: Local T cell neighbourhoods determine outcome in non-small cell lung cancer treatment with KRAS-G12C inhibitors. Timely….
0
14
0
RT @CellPressNews: Exploiting the therapeutic implications of KRAS inhibition on tumor immunity - check out this review from @TheCrick @Jul….
cell.com
New drugs targeting the KRAS oncoprotein provide only short-term clinical benefit. Molina-Arcas and Downward review how oncogenic KRAS creates an immune-suppressive tumor microenvironment, providing...
0
26
0